Definition and scope of service
Polysomnography, or PSG, is a study that records multiple physiologic signals together during a planned sleep period. A typical attended laboratory PSG records electroencephalography, eye movements, chin and leg muscle activity, airflow, chest and abdominal respiratory effort, oxygen saturation, heart rate or electrocardiography, and body position. Selected protocols may add audio, video, or carbon-dioxide monitoring. These signals identify actual sleep time and stages and help characterize sleep-related breathing, movement, unusual behavior, and selected nocturnal events. The montage and protocol should match the person's age, suspected condition, institutional standards, and clinical question.
PSG is a diagnostic tool, not a universal checkup that resolves every sleep concern in one night. It cannot directly measure dreams, sleep satisfaction, or every aspect of daytime function, and one number cannot explain fatigue, insomnia, or sleepiness by itself. A complete PSG service commonly includes referral review, pretest assessment, sensor application, overnight quality monitoring, manual scoring, professional interpretation, and communication of results. Selling a device, producing an automated summary, or supplying a list of uninterpreted metrics is not equivalent to that clinical service.
Indications and choice of test
PSG can diagnose and classify obstructive or central sleep apnea, sleep-related hypoventilation, and sleep-related hypoxemia when a comprehensive evaluation raises concern. Laboratory PSG is often more appropriate than limited-channel home testing when there is significant cardiorespiratory disease, possible respiratory muscle weakness, awake or suspected sleep-related hypoventilation, chronic opioid use, prior stroke, severe insomnia, or a need to evaluate an important nonrespiratory disorder. Complex nocturnal behavior, possible sleep-related epilepsy, periodic limb movements, or central hypersomnolence may also call for a targeted PSG or expanded montage.
Not every person with snoring or insomnia needs immediate PSG. Some uncomplicated adults at increased risk of moderate-to-severe obstructive sleep apnea can use a technically adequate home sleep apnea test under professional management. Home testing generally records fewer signals and is not interchangeable with full PSG. If one home study is negative, inconclusive, or technically inadequate while clinical suspicion remains, PSG should be considered. Questionnaires, phone applications, smartwatches, and standalone overnight oximetry may support screening or provide clues, but they should not independently diagnose obstructive sleep apnea.
Pretest assessment and preparation
Before scheduling, the service should state the question being addressed: a full-night diagnostic study, a split-night diagnostic and titration protocol, a dedicated PAP titration, or a baseline night for a next-day multiple sleep latency test, for example. History includes sleep timing, snoring and pauses, unusual movements, dream-enactment behavior, seizure history, cardiopulmonary or neuromuscular disease, pregnancy, skin allergy, mobility and communication needs, and recent infection. Every prescription and nonprescription medicine, caffeine, alcohol, nicotine, and other substance should be reported because each may change sleep architecture, breathing, leg movements, or next-day sleepiness testing.
Patients should not deprive themselves of sleep to “make the problem show up” or independently stop a sedative, antidepressant, stimulant, opioid, or cardiopulmonary medicine. Changes should follow written instructions from the referring team. The facility should explain requirements for hair washing, hairstyles, skin products, meals, beverages, routine medicines, and items to bring and whether a familiar mask, assistive device, or caregiver is needed. Children, people with cognitive or mobility limitations, and anyone with an accessibility need should discuss caregiver presence, adaptation to sensor placement, bathroom assistance, and emergency planning in advance.
Monitoring process and quality control
At the laboratory, a technologist confirms identity, protocol, and safety information, applies removable sensors to the scalp, around the eyes, chin, chest and abdomen, legs, and finger, and performs calibrations. Leads are arranged to allow position changes, and the patient can contact the technologist through a call system. Throughout the night, the technologist watches for detached signals, artifact, respiratory events, and behavior and can reapply sensors when needed. PSG is generally noninvasive and painless, although adhesive, nasal cannulae, belts, and an unfamiliar setting can cause minor skin irritation or alter usual sleep.
A split-night study proceeds to PAP titration only if the first part provides enough diagnostic evidence and enough time remains for a meaningful titration; it should not be promised to every patient. Pressure, mask, and ventilation mode depend on protocol and observed response rather than another person's settings. Record quality depends not only on duration but also on actual sleep, adequate sampling of position and sleep stages, continuous function of critical channels, and documentation of medicines, oxygen, and assistive devices. Lost signals or too little sleep may limit interpretation and sometimes require a repeat study or a different approach.
Metrics, interpretation, and evidence boundaries
A report commonly describes total sleep time, sleep efficiency, stages and arousals, apnea-hypopnea index, event types, position and sleep-stage distribution, oxygen changes, heart rate or rhythm, limb movements, and observed behavior. The denominator for an event index, hypopnea scoring rule, age-specific standard, and recording method all affect results. Laboratory PSG, home tests, different laboratories, and studies from different periods should therefore not be compared mechanically by one number. A lowest oxygen value may also reflect a displaced sensor, poor peripheral perfusion, or artifact and must be interpreted with the source tracing and event duration.
One night is influenced by an unfamiliar environment, departure from the usual schedule, sleep position, alcohol and medicines, nasal congestion, illness, and night-to-night variability. A negative PSG does not permanently exclude obstructive sleep apnea when clinical suspicion remains high. Limb movements do not automatically establish restless legs syndrome, and a nocturnal movement or rhythm signal does not necessarily make a neurologic or cardiac diagnosis. Automated scoring may support efficiency, but qualified review is needed, incorporating technical quality, history, and symptoms. PSG contributes to clinical reasoning; it is not a judgment detached from the patient.
Reporting, follow-up, and data stewardship
After acquisition, a technologist commonly marks sleep stages and events using standardized rules, and an appropriately qualified clinician reviews the study and issues a report. Results should state whether the clinical question was answered, whether the record was adequate, the main findings, remaining uncertainty, and whether the next step is treatment discussion, additional testing, repeat PSG, or referral elsewhere. For central hypersomnolence such as suspected narcolepsy, a multiple sleep latency test generally requires a protocol-compliant preceding PSG and sleep schedule; simply falling asleep quickly during an ordinary overnight PSG does not establish that diagnosis.
Options after diagnosis may include PAP, an oral appliance, positional or weight intervention, surgical assessment, medication review, or condition-specific management of behavior, movement, or neurologic events. Choice depends on the condition and the patient's preferences. The center should explain access to reports, correction procedures, privacy, and data retention, especially for video, audio, and physiologic signals. Insurance authorization, cost, and turnaround time should be transparent before testing when possible, but payment rules do not replace a clinical indication. Major change in symptoms, weight, health, or treatment response may prompt a fresh decision about retesting.
Safety, privacy, and urgent boundaries
Before testing, patients should report allergy to electrode paste, adhesive, or latex and disclose fall risk, seizures, nighttime diabetes medicines, oxygen therapy, and implanted devices. Sensors should not obstruct emergency exits or prevent safe movement. Anyone needing nighttime medicines, glucose monitoring, assisted ventilation, or caregiving help should have a clear plan with the facility. The laboratory should explain whether recording includes video, who can view it, how long it is retained, and how to request a copy. Patients may request privacy, gender-concordant care, and accessibility support, but should not remove essential sensors and assume the remaining record is valid.
Persistent chest pain, severe breathing difficulty, blue discoloration, prolonged or recurrent seizure without recovery, severe hypoglycemia, acute confusion, or inability to awaken requires immediate emergency response under the facility's protocol rather than continuing the study for completeness. A patient too sleep-deprived or sleepy to drive after the study should arrange safe transportation. Mild electrode-site irritation is usually brief, but persistent rash, skin breakdown, or signs of infection warrant medical advice. The first purpose of a PSG service is to obtain interpretable data safely, not to finish a night at any cost or assign every patient a diagnosis.